J&J beats earnings estimates; Middle East conflict weighs on medical-device sales

Johnson & Johnson reported Q3 revenue of $25.4B versus $25.28B expected and adjusted EPS of $2.59 versus $2.54, led by Tremfya sales up 68% to $2.4B. It raised its full-year sales forecast midpoint by $0.1B to about $101.2B and adjusted EPS midpoint by $0.06 to $11.10, while medical-technology sales grew 2.5% amid international headwinds and Darzalex missed estimates. Shares had risen 27% year to date through Monday’s close at $263.73.

Analysis

The key distinction is between a pharmaceutical portfolio that is successfully absorbing a known product transition and a medtech business facing a mix of budget pressure and product-specific evidence risk. Tremfya’s acceleration reduces near-term Stelara-cliff risk, but the Darzalex miss is a reminder that pharma growth is not uniformly strong; monitor whether Tremfya can sustain the replacement pace rather than extrapolating one quarter. In medtech, defense-led budget reallocation could defer premium-device purchases beyond the immediate conflict, while the Abiomed/Impella concern is a separate, potentially longer-lived adoption issue. Treating all international weakness as temporary would understate that risk.

The small guidance lift offers limited new evidence against a share price that has already materially outperformed this year. Near term, the beat may support the stock, but the 1–3 month test is follow-through in Tremfya and whether Darzalex expectations reset. Over 6–18 months, the central question is whether pharma growth can compensate for subdued medtech and the Stelara erosion without relying on continued outsized Tremfya gains. The contrarian risk is that investors may focus on the successful Stelara transition and discount device weakness as geopolitical noise; conversely, sustained Tremfya execution could make the quarter’s modest outlook increase look unduly cautious. No valuation data here establishes that the shares are mispriced.

Key Decisions for Investors

• Do not chase the post-results strength; keep JNJ at benchmark weight or trim excess relative exposure rather than adding on a modest forecast lift after strong year-to-date performance.
• Revisit a long on a pullback only if subsequent disclosures confirm continued Tremfya growth and stabilization in the Stelara transition. Falsify that setup if Tremfya momentum slows or management lowers the sales outlook.
• Track medtech sales by geography and Abiomed/Impella utilization or new clinical evidence separately. A recovery in international orders would support the view that budget disruption is temporary; continued weakness or adverse evidence would argue for a more durable device discount.